E-LIB Suche - Ergebnisse für: Bagel, J

1

POSC7 Work Productivity and Activity Impairment for Patient..:

Thaçi, D ; Bagel, J ; Węgłowska, J...
Value in Health. 25 (2022) 1 - p. S33 , 2022

Link: https://doi.org/10.1016/..

2

Strain- and serotype-dependent affinity of Shiga toxin-prod..:

Bagel, A. ; Delignette-Muller, M.-L. ; Lopez, C....
Journal of Dairy Science. 105 (2022) 11 - p. 8688-8704 , 2022

Link: https://doi.org/10.3168/..

3

IGAxBSA composite for assessing disease severity and respon..:

Paller, A.S. ; Tan, J.K.L. ; Bagel, J....
British Journal of Dermatology. 186 (2022) 3 - p. 496-507 , 2022

Link: https://doi.org/10.1111/..

4

Effect of baseline disease severity on achievement of treat..:

Reich, K. ; Mrowietz, U. ; Menter, A....
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 12 - p. 2409-2414 , 2021

Link: https://doi.org/10.1111/..

5

Efficacy and safety of apremilast in patients with moderate..:

Van Voorhees, A.S. ; Stein Gold, L. ; Lebwohl, M....
British Journal of Dermatology. 185 (2021) 4 - p. 840-842 , 2021

Link: https://doi.org/10.1111/..

6

Bimekizumab Efficacy and Safety versus Adalimumab in Patien..:

Warren, RB ; Blauvelt, A ; Bagel, J...
SKIN The Journal of Cutaneous Medicine. 5 (2021) 1 - p. s15 , 2021

Link: https://doi.org/10.25251..

7

PSS18 Real-World Data Analysis of Dose Escalation and Assoc..:

Bagel, J. ; Glick, B. ; Wu, J.J....
Value in Health. 24 (2021) - p. S223 , 2021

Link: https://doi.org/10.1016/..

8

Secukinumab maintains superiority over ustekinumab in clear..:

Bagel, J. ; Blauvelt, A. ; Nia, J....
Journal of the European Academy of Dermatology and Venereology. 35 (2020) 1 - p. 135-142 , 2020

Link: https://doi.org/10.1111/..

9

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究:

Blauvelt, A. ; Papp, K. ; Gottlieb, A....
British Journal of Dermatology. 182 (2020) 6 - p. , 2020

Link: https://doi.org/10.1111/..

10

The National Psoriasis Foundation psoriasis treatment targe..:

Merola, J.F. ; Perez Chada, L.M. ; Siegel, M....
Journal of the European Academy of Dermatology and Venereology. 34 (2020) 9 - p. 2051-2058 , 2020

Link: https://doi.org/10.1111/..

11

A study comparing the biologic drugs ixekizumab and guselku..:

Blauvelt, A. ; Papp, K. ; Gottlieb, A....
British Journal of Dermatology. 182 (2020) 6 - p. , 2020

Link: https://doi.org/10.1111/..

12

A head‐to‐head comparison of ixekizumab vs. guselkumab in p..:

Blauvelt, A. ; Papp, K. ; Gottlieb, A....
British Journal of Dermatology. 182 (2020) 6 - p. 1348-1358 , 2020

Link: https://doi.org/10.1111/..

13

Efficacy and safety of ixekizumab in a phaseIII, randomized..:

Paller, A.S. ; Seyger, M.M.B. ; Alejandro Magariños, G....
British Journal of Dermatology. 183 (2020) 2 - p. 231-241 , 2020

Link: https://doi.org/10.1111/..

14

Efficacité à long terme de l'ixékizumab et amélioration du ..:

Wu, J.J. ; Bagel, J. ; Langley, R.G....
Annales de Dermatologie et de Vénéréologie. 146 (2019) 12 - p. A339-A340 , 2019

Link: https://doi.org/10.1016/..

15

Constance de la réponse selon l'âge chez des patients attei..:

Kontantinou, M.P. ; Armstrong, A. ; Poulin, Y....
Annales de Dermatologie et de Vénéréologie. 146 (2019) 12 - p. A335 , 2019

Link: https://doi.org/10.1016/..